Mark Kotter is a clinician scientist at the University of Cambridge with an interest in neural stem cells and cellular reprogramming. His early research demonstrated an unexpected role of the innate immune system for regenerative processes in the CNS and has triggered a new field investigating the immune regulation of remyelination. His laboratory recently described a number of mechanisms for enhancing the regeneration of myelin sheaths by promoting the differentiation of stem cells. One of these approaches is currently tested in RECEDE Myelopathy, the first regenerative medicine trial for degenerative cervical myelopathy, a common and disabling disease affecting the spinal cord.
Focussed on translation, his laboratory has developed a keen interest in cellular reprogramming. His latest research uncovered a method which renders cell type conversions robust and highly scalable. These findings form the basis of two spin out companies.